Published in J Skin Cancer on November 17, 2011
Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer (2015) 0.85
Comparison of Three BRAF Mutation Tests in Formalin-Fixed Paraffin Embedded Clinical Samples. Korean J Pathol (2013) 0.85
Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. Cancer Manag Res (2014) 0.81
Lynch syndrome: clinical, pathological, and genetic insights. Langenbecks Arch Surg (2012) 0.78
Identification of the serine biosynthesis pathway as a critical component of BRAF inhibitor resistance of melanoma, pancreatic, and non-small cell lung cancer cells. Mol Cancer Ther (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet (2009) 5.01
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res (2006) 4.29
Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst (2001) 4.25
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res (2006) 3.00
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res (2005) 2.98
The MAPK pathway in melanoma. Curr Opin Oncol (2008) 2.80
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res (2003) 2.72
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol (2010) 2.60
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res (2010) 2.31
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res (2010) 2.17
Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature (1984) 2.14
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A (2002) 2.13
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res (2010) 2.02
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res (2008) 1.99
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res (2003) 1.86
A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res (2006) 1.85
Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer (2011) 1.73
A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res (2010) 1.68
Raf: a strategic target for therapeutic development against cancer. J Clin Oncol (2005) 1.63
N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol (1989) 1.61
Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene (2010) 1.57
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer (2009) 1.50
Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol (1994) 1.50
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia (2010) 1.48
Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. Cancer Res (2011) 1.40
Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes (2004) 1.39
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res (2007) 1.33
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer (2012) 1.32
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res (2009) 1.30
Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis (2010) 1.25
Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn (2007) 1.18
Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol (2004) 1.13
Customized care 2020: how medical sequencing and network biology will enable personalized medicine. F1000 Biol Rep (2009) 1.12
SNP genotyping using Sequenom MassARRAY 7K platform. Curr Protoc Hum Genet (2004) 1.08
mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin Chem (2009) 1.07
Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer (2007) 1.06
Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin Cancer Res (2008) 1.01
BRAFV600E detection in melanoma is highly improved by COLD-PCR. Clin Chim Acta (2011) 0.98
Selective amplification of rare mutations using locked nucleic acid oligonucleotides that competitively inhibit primer binding to wild-type DNA. J Invest Dermatol (2007) 0.89
An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood. Melanoma Res (2010) 0.85
Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients. Clin Chim Acta (2010) 0.83
Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res (1994) 0.82
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol (2008) 5.31
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell (2008) 4.84
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol (2006) 3.59
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 3.38
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92
The MAPK pathway in melanoma. Curr Opin Oncol (2008) 2.80
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov (2013) 2.61
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med (2012) 2.26
Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer (2013) 2.23
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol (2012) 2.21
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer (2014) 2.12
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol (2011) 2.10
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res (2007) 1.81
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol (2011) 1.77
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol (2008) 1.71
Vemurafenib. Nat Rev Drug Discov (2011) 1.68
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med (2013) 1.67
Genetic alterations and personalized medicine in melanoma: progress and future prospects. J Natl Cancer Inst (2014) 1.61
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res (2007) 1.58
Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res (2009) 1.57
Melanoma: new insights and new therapies. J Invest Dermatol (2012) 1.54
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov (2013) 1.52
Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res (2011) 1.47
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res (2008) 1.39
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol (2008) 1.35
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res (2009) 1.30
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol (2010) 1.30
HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res (2007) 1.28
CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res (2007) 1.26
BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res (2012) 1.22
Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer (2011) 1.21
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
BRAF in melanoma: current strategies and future directions. Clin Cancer Res (2013) 1.16
A melanoma molecular disease model. PLoS One (2011) 1.15
CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther (2013) 1.13
BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology (2013) 1.13
Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res (2005) 1.12
New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res (2011) 1.12
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol (2010) 1.12
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest (2015) 1.11
The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res (2013) 1.10
Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nat Rev Drug Discov (2013) 1.10
Ipilimumab for patients with advanced mucosal melanoma. Oncologist (2013) 1.09
Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol (2012) 1.08
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol (2009) 1.08
Biological challenges of BRAF inhibitor therapy. Mol Oncol (2011) 1.08
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res (2007) 1.07
Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res (2012) 1.06
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin Cancer Res (2009) 1.03
Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin Cancer Res (2006) 1.01
Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res (2009) 1.00
Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res (2014) 0.99
Targeting the RAS pathway in melanoma. Trends Mol Med (2011) 0.98
PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget (2014) 0.94
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs (2009) 0.94
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest (2016) 0.93
Targeted molecular therapy in melanoma. Semin Cutan Med Surg (2010) 0.92
Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol (2014) 0.91
Where are we with adjuvant therapy of stage III and IV melanoma in 2009? J Natl Compr Canc Netw (2009) 0.90
Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol (2013) 0.90
Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. Future Oncol (2009) 0.90
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One (2013) 0.90
Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell Melanoma Res (2014) 0.89
Targeted therapy for metastatic melanoma. Clin Adv Hematol Oncol (2007) 0.86
Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol (2012) 0.85
MEK and RAF inhibitors for BRAF-mutated cancers. Expert Rev Mol Med (2012) 0.85
Molecular therapeutic approaches to melanoma. Mol Aspects Med (2010) 0.84
Cyclin-dependent kinases as therapeutic targets in melanoma. Pigment Cell Melanoma Res (2014) 0.84
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. AJR Am J Roentgenol (2013) 0.82
Meeting report from the 2011 International Melanoma Congress, Tampa, Florida. Pigment Cell Melanoma Res (2011) 0.81
Hyperspectral imaging: a non-invasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with a RAF inhibitor. Cancer Biol Ther (2011) 0.81
Major response to everolimus in melanoma with acquired imatinib resistance. J Clin Oncol (2011) 0.81
Throwing the kitchen sink at melanoma drug development. Pigment Cell Melanoma Res (2012) 0.79
Drug targeting of oncogenic pathways in melanoma. Hematol Oncol Clin North Am (2009) 0.79
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer (2013) 0.78
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. PLoS One (2013) 0.78
Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies. Cancer Chemother Pharmacol (2004) 0.78